<p>A. Body weight loss in vaccinated/challenged C57/B6 mice. Mice were vaccinated with Pol1, Pol2, A/PR8 or mock vaccinated and challenged intraperitoneally on day 21 post-immunization with a lethal dose of A/PR8 (1×10<sup>7</sup> pfu ). Body weight was monitored daily. B. Survival rate of mice immunized by Pol1, Pol2, A/PR8 against lethal dosage challenge.</p
<p>Mice were vaccinated once with mammalian cell-, or baculovirus- derived VLPs containing 50 ng of ...
<p>Immunized mice were challenged with a lethal dose (40 LD<sub>50</sub>) of A/PR8 (<b>A</b> and <b>...
<p>Six—eight weeks old female BALB/c mice (n = 6 per group) were immunized with 10<sup>10</sup> f88M...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>(A–B) At six months after prime-boost immunizations with M2 VLPs, mice (n = 5) were challenged wi...
<p>Mice that were administered AF, infected with 1LD<sub>50</sub> of PR/8 virus or immunized with 1,...
<p>(A–B) Groups of vaccinated mice and a mock control were intranasally challenged with a lethal dos...
<p>At week 5, mock vaccinated mice or mice vaccinated with vaccines (3 µg) were challenged intranasa...
<p>Groups of mice (n = 4) were immunized 1 or 2 times, 4 weeks apart, with IDLV-NP via either the i....
<p>Six—eight weeks old female BALB/c mice (n = 10 per group) were immunized with 10<sup>10</sup> f88...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>BALB/c mice (n = 6) were immunized on day 0 and 21 with rNP (10 µg/dose) alone or co-administered...
<p>At week 30 post immunization, H5N1 VLP immunized and control (PBS or 5 µg inactivated PR/8/34 H1N...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>Mice were vaccinated once with mammalian cell-, or baculovirus- derived VLPs containing 50 ng of ...
<p>Immunized mice were challenged with a lethal dose (40 LD<sub>50</sub>) of A/PR8 (<b>A</b> and <b>...
<p>Six—eight weeks old female BALB/c mice (n = 6 per group) were immunized with 10<sup>10</sup> f88M...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>(A–B) At six months after prime-boost immunizations with M2 VLPs, mice (n = 5) were challenged wi...
<p>Mice that were administered AF, infected with 1LD<sub>50</sub> of PR/8 virus or immunized with 1,...
<p>(A–B) Groups of vaccinated mice and a mock control were intranasally challenged with a lethal dos...
<p>At week 5, mock vaccinated mice or mice vaccinated with vaccines (3 µg) were challenged intranasa...
<p>Groups of mice (n = 4) were immunized 1 or 2 times, 4 weeks apart, with IDLV-NP via either the i....
<p>Six—eight weeks old female BALB/c mice (n = 10 per group) were immunized with 10<sup>10</sup> f88...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>BALB/c mice (n = 6) were immunized on day 0 and 21 with rNP (10 µg/dose) alone or co-administered...
<p>At week 30 post immunization, H5N1 VLP immunized and control (PBS or 5 µg inactivated PR/8/34 H1N...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>Mice were vaccinated once with mammalian cell-, or baculovirus- derived VLPs containing 50 ng of ...
<p>Immunized mice were challenged with a lethal dose (40 LD<sub>50</sub>) of A/PR8 (<b>A</b> and <b>...
<p>Six—eight weeks old female BALB/c mice (n = 6 per group) were immunized with 10<sup>10</sup> f88M...